ErbB2/HER2 Antibody (9G6): sc-08

Neu Antibody (9G6) is a mouse monoclonal IgG1 antibody raised against human Neu (ErbB-2/HER2), a crucial member of the epidermal growth factor receptor family of receptor tyrosine kinases. Neu mouse monoclonal antibody (9G6) recognizes an epitope within the Neu immunogen sequence and demonstrates specificity for human samples through Western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry on paraffin-embedded sections (IHCP), and flow cytometry (FCM) applications. Anti-Neu monoclonal antibody (9G6) is available in non-conjugated form for experimental flexibility. Neu′s sophisticated function depends on precise localization to the cell membrane, where Neu regulates complex signaling networks controlling cell growth, differentiation, and survival. A particularly significant aspect of Neu′s function involves forming heterodimers with other EGFR family members, especially ErbB-3. These heterodimer complexes amplify signaling pathways, including the phosphoinositide 3-kinase cascade, which can promote tumor cell motility and invasion when dysregulated. The clinical significance of Neu becomes evident in breast cancer, where Neu amplification or overexpression occurs in 20-30% of carcinomas, often correlating with more aggressive disease progression. This prevalent involvement in cancer biology makes Neu both an important prognostic biomarker and a critical therapeutic target. Through these diverse cellular roles and clinical implications, Neu (9G6) antibody provides researchers with a valuable tool for investigating cancer mechanisms and developing targeted treatments.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

ErbB2/HER2 Antibody (9G6) References:

1. The basic biology of HER2.  |  Rubin, I. and Yarden, Y. 2001. Ann Oncol. 12 Suppl 1: S3-8. PMID: 11521719
2. Heregulin-dependent activation of phosphoinositide 3-kinase and Akt via the ErbB2/ErbB3 co-receptor.  |  Hellyer, NJ., et al. 2001. J Biol Chem. 276: 42153-61. PMID: 11546794
3. HER-2/neu-derived peptide epitopes are also recognized by cytotoxic CD3(+)CD56(+) (natural killer T) lymphocytes.  |  Baxevanis, CN., et al. 2002. Int J Cancer. 98: 864-72. PMID: 11948464
4. The role of c-erbB-2/HER2/neu in breast cancer progression and metastasis.  |  Eccles, SA. 2001. J Mammary Gland Biol Neoplasia. 6: 393-406. PMID: 12013529
5. Gene amplification and mRNA and protein overexpression of c-erbB-2 (HER-2/neu) in human intrahepatic cholangiocarcinoma as detected by fluorescence in situ hybridization, in situ hybridization, and immunohistochemistry.  |  Ukita, Y., et al. 2002. J Hepatol. 36: 780-5. PMID: 12044528
6. c-erbB-2 in breast cancer: development of a clinically useful marker.  |  Hayes, DF. and Thor, AD. 2002. Semin Oncol. 29: 231-45. PMID: 12063676
7. Colonic epithelial expression of ErbB2 is required for postnatal maintenance of the enteric nervous system.  |  Crone, SA., et al. 2003. Neuron. 37: 29-40. PMID: 12526770
8. Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab.  |  Cho, HS., et al. 2003. Nature. 421: 756-60. PMID: 12610629
9. Synapses form in skeletal muscles lacking neuregulin receptors.  |  Escher, P., et al. 2005. Science. 308: 1920-3. PMID: 15976301
10. Dual inhibition of ErbB1 (EGFR/HER1) and ErbB2 (HER2/neu).  |  Reid, A., et al. 2007. Eur J Cancer. 43: 481-9. PMID: 17208435
11. Small molecule tyrosine kinase inhibitors of ErbB2/HER2/Neu in the treatment of aggressive breast cancer.  |  Schroeder, RL., et al. 2014. Molecules. 19: 15196-212. PMID: 25251190
12. EGFR/ErbB2-Targeting Lapatinib Therapy for Aggressive Prolactinomas.  |  Cooper, O., et al. 2021. J Clin Endocrinol Metab. 106: e917-e925. PMID: 33150390